# Pfizer remains a high-conviction, undervalued Strong Buy with a robust pipeline and aggressive growth in oncology and obesity platforms.

*biotech · news · 2026-05-01 · Seeking Alpha*

## Key points

- Pfizer reaffirmed its 2026 revenue guidance of $59.5–$62.5 billion and EPS of $2.8–$3.
- Management is aggressively onshoring high-margin production to combat loss-of-exclusivity headwinds.
- Pfizer is prioritizing cost-cutting measures to expand operating margins through 2027.
- Current valuation is 8.13x P/E and 6.4% dividend yield, outpacing industry peers.

**Companies:** Pfizer

[Read the full story on Seeking Alpha](https://seekingalpha.com/article/4897344-pfizer-why-you-should-double-down-into-q1)

---

Canonical: https://newsio.io/n/548f5151-2188-441c-abb5-827dc8166326/pfizer-remains-a-high-conviction-undervalued-strong-buy-with-a-robust-pipeline-a
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works